View all veterinary jobs
Krka says Prazemo is the first generic to offer this combination of actives in this format, and is bioequivalent to the originator product.
Prazemo is available in three dosage strengths for different cat weights and can be used from 8 weeks of age and during pregnancy and lactation.
For cats that also require ectoparasiticide treatment, it can be used alongside a mono-isoxazoline (fluralaner) treatment.
Will Ridgway, Head of Animal Health at Krka UK, said: "Prazemo strengthens our feline parasiticide portfolio with an effective spot-on solution that veterinary practices can be confident delivers affordability combined with Krka’s high standards of product efficacy and supply chain control."
For more information, email: animalhealth.uk@krka.biz
The online invitation survey was conducted among 6,500 pet owners from around the world, 1,000 of whom were based in the UK.
Whilst the survey didn't glean any further information about the nature of the infections, such as what percent of them were endoparasites versus ectoparasites, it did reveal that 61% of respondents said their pet experienced discomfort or illness, 39% said they showed behavioural changes and 38% reported that it made them feel anxious.
However, 38% see a parasite infection as not serious or just slightly serious.
Seventy per cent of owners said they get their parasite information from vets, compared to 43% from the internet.
Forty-five per cent use prescription treatments and 40% use vet-administered treatments in a clinic.
According to the company, 71% of UK pet owners said they would like clearer guidance on parasite protection, yet 35% have not been informed about parasite risks in their area by their vet.
Ian Wright MRCVS, Chairman/Director of ESCCAP (European Scientific Counsel Companion Animal Parasites), said: "It has never been more important to be aware of parasites and the risk to companion animals – the increased movement of pets and people, as well as climate change, has fuelled a rapid shift in the distribution of parasites and their proximity to pets.
"Pets can carry parasites which affect animal and human health - although there are familiar types, such as fleas – we need to be vigilant for unexpected parasites moving into new countries and regions.
"With simple precautions and preventative measures, we can minimise the risk of diseases they may bring, and continue to enjoy the wonderful benefits of pet ownership."
The sessions are aimed at vets, vet nurses, SQPs and RAMAs involved in anthelmintic prescribing, and are designed to support implementation of new sustainable equine parasite control guidelines from the BEVA and Canter.
The webinars will be presented by Professor Jacqui Matthews, an RCVS Recognised Specialist in Parasitology, and Dr Wendy Talbot, Zoetis RCVS and European Specialist in Internal Medicine.
Participants can submit real-world case scenarios for discussion by emailing details to wendy.talbot@zoetis.com at least four weeks before each webinar. There is no obligation for case submitters to speak during the webinar.
The remaining scheduled sessions are:
The webinar series can be recorded as self-reflective CPD.
https://canterforhorses.org.uk/guidelines/
https://www.beva.org.uk/Resources/Medicines/Anthelmintic-Toolkit
That'll bring the GB list price down from £434 to £347.20, something which can only be good news at a time when the veterinary profession is facing greater scrutiny over the cost of care than ever before.
The company says it will also be increasing the product discount, which can be discussed with its Account Managers.
MSD says the price drop makes Bravecto Injectable the most affordable way to protect dogs with Fluralaner and highlights the convenience of annual dosing and the fact that it avoids tricky discussions about where to buy the product.
https://www.msd-animal-health.co.uk/
The webinar will be presented by Jenny Helm Cert SAM Dip ECVIM-CA FHEA MRCVS EBVS and RCVS Specialist in Small Animal Medicine.
Jenny will explain the latest knowledge about lungworm in dogs, including an update on prevalence, clinical case management and treatment and prevention options.
Louise Longstaff, National Veterinary Manager at Zoetis said: “Jenny will not only cover some of the challenges with diagnosing lungworm but will also discuss the latest prevention strategies including the use of Simparica Trio."
https://cloud.mc.zoetis.com/LungWormWebinar2025
The company says the new framework is designed to help veterinary teams make prescribing decisions which balance animal welfare, public health, and environmental sustainability, the latter especially in the light of recent research which found significant levels of imidacloprid and fipronil - which are toxic to invertebrates - in waterways1,2.
The Lifestyle Parasite Risk Assessment considers the following factors before recommending treatment, including:
Pet-specific behaviours such as scavenging, hunting, or eating raw foodEnvironmental exposure, including outdoor access and swimming habitsHousehold composition, especially the presence of vulnerable individualsTravel history, both domestic and internationalOwner compliance and preferred administration methods
Alongside the new assessment, CVS has launched a training course for all staff who interact with parasiticides, so they can confidently explain the benefits of lifestyle-based prescribing.
References
ParaProtect offers bitesize interactive learning modules, each taking 20 to 30 minutes to complete.
The programme is open to all practice staff, from vets and nurses to client care teams, and aims to advance parasitology expertise and build further confidence in risk-based parasite protection.
Elanco says each module includes expert insights, real-world case studies and practical advice that can be applied immediately in practice.
The first module: ‘Parasite Control in a One Health World’, explores the wider implications of parasite control, including risks to public health from parasites, and consideration for the environment when selecting and using parasiticides.
Later modules will cover topics such as the impact of climate and travel on parasite spread, myth-busting, emerging risks, and how to improve client communication and compliance.
Jacqui Skelly, Head of Veterinary Technical Services, UK & Ireland at Elanco, said: “Parasitology is a field of medicine that most vets are practicing many times a day, yet it’s easy to neglect when it comes to CPD.
“As parasite risks evolve alongside climate and behavioural change, there’s growing demand for CPD that reflects current science and supports evidence-based decision making in practice.
"With ParaProtect, we aim to service that need with a different kind of programme.
"It’s short, practical, relevant and designed to be used straight away in the consulting room.
"It has principles of responsible use of parasiticides built into the core of the learning, and helps teams move beyond routine treatment to deliver advice that protects pets and their families, especially as summer travel increases parasite risks.”
https://my.elanco.com/en_gb/campaign/pet/paraprotect
Photo: www.depositphotos.com
This, the company says, makes Simparica Trio the only oral moxidectin that is licensed to treat A.vasorum in dogs in the UK.
Louise Longstaff, National Veterinary Manager at Zoetis UK said: “The last time a product was licensed for the treatment of lungworm in the UK was some time ago, so this is an especially important development.
"Simparica Trio offers a new licensed route of administration for lungworm treatment in dogs, giving vets another option to that which is currently available.
"It enables them to tailor treatment based on their patient’s needs while still prescribing within the cascade.”
Simparica Trio is a chewable monthly tablet for dogs containing sarolaner, moxidectin and pyrantel.
It kills fleas and ticks, treats mites, roundworm and hookworm, prevents and treats lungworm and prevents heartworm disease.
https://www.noahcompendium.co.uk/?id=-485011
The working group, which is led by Gudrun Ravetz, IVC's Group Chief Medical Officer, has been tasked with developing evidence-based, sustainable prescribing practices that protect animal health while safeguarding the planet.
The group comprises experts from within IVC Evidensia’s network who will collaborate with industry and academic partners including Vetoquinol, IDEXX, ESCCAP, and MSD Animal Health to deliver research, education, and practical tools for veterinary teams both inside and outside of IVC Evidensia practices.
Gudrun said: “We’re proud to be investing in this work and setting an example for the profession.
"Responsible parasiticide use is not just a clinical issue, it’s a sustainability imperative.”
In the webinar, which is sponsored by Horiba, Ian will present an update on new exotic parasite infections and distribution across the UK and Europe, and what this means for pets, livestock and the people that care for them.
“New Exotic Parasites – Worming Their Way In?” is suitable for vets, nurses, students and veterinary care assistants.
https://horiba.link/4h2.
The maps provide vets with a visual representation of targeted diagnostic tests conducted in France, Germany, Ireland, Italy, Spain, and the UK, using data sourced from Idexx.
They show the percentage of positive test results for a range of parasites and parasite-associated infections in dogs and cats, including Giardia, roundworm, and whipworm, and Lyme (Borrelia burgdorferi), Ehrlichia spp., Anaplasma spp., Babesia spp., and Leishmania in dogs.
Data can be filtered by country, region, animal species, parasite type, and time period.
ESCCAP highlights that the data reflects the percentage of positive tests in screened animals, not the overall prevalence of infection.
https://www.esccap.org/parasite-infection-map/
ESCCAP says that the risk of novel parasites and zoonoses spreading to new regions has risen alongside an increase in pet travel and changing climate conditions.
ESCCAP’s Guideline 09 offers detailed advice on how to protect dogs and cats that travel or are imported across European borders, minimise the risk of zoonotic transmission and prevent the establishment of new parasites in previously unaffected areas.
Topics covered in the guideline include:
The guideline emphasises the importance of early detection of parasitic infections by thorough clinical examinations, comprehensive travel history assessments and targeted diagnostic testing.
It also provides guidance on educating pet owners about zoonotic risks and implementing appropriate treatments and follow-up screenings.
www.esccap.org/guidelines/gl9/
The study is being conducted with pet owners and veterinary professionals to develop a greater understanding about how flea and tick treatments are used on cats and dogs.
It will involve two depth surveys to explore the type and format of treatments used, the frequency of application, where treatments are bought, what influences the choice of product, whether there is an awareness of ectoparasiticides’ environmental effect and what preventative steps the public and clinicians would take when using the treatments on animals in the future.
At a later stage, the research project will also include lab assessments of ectoparasiticide residues collected from companion animals to provide more information on their potential environmental impact.
It is hoped the research findings will help the veterinary profession develop the most appropriate approaches to ectoparasiticides in the future, and inform educational strategies to support owners with ‘responsible use’.
Project leader Professor Richard Wall from the University of Bristol, said: “This is an issue of considerable concern.
"Citizen science and laboratory research evidence is urgently needed so that risk-based assessments of the impact of and requirements for ectoparasite treatment can be made.
"Whilst we can make some assumptions around the impact of routine ectoparasite treatments, these findings are essential for us to truly understand them - and to be able to balance the needs of veterinary patients with their wider environmental impacts.”
https://forms.office.com/e/mbztbYf4Ru.
Bravecto Triuno is approved for the treatment of tick and flea infestations in dogs (Ctenocephalides felis, C. canis, Dermacentor reticulatus, Ixodes hexagonus, Ixodes ricinus, and Rhipicephalus sanguineus).
It is also approved for the treatment of infections with roundworms (adult stages of Toxocara canis and Toxascaris leonina) and hookworms (L4, immature adult (L5), and adult stages of Ancylostoma caninum and Uncinaria stenocephala), for the prevention of heartworm disease (caused by Dirofilaria immitis), and for the prevention of angiostrongylosis (by reduction of the level of infection with immature adult (L5) and adult stages of Angiostrongylus vasorum).
Victoria Miles, UK Companion Animal Director, MSD Animal Health, said: “With this latest formulation of Bravecto, MSD Animal Health is giving veterinarians and dog owners a greater range of convenient options for protecting their dog year-round from parasites, and all from the same trusted Bravecto portfolio.”
She added: “We see Bravecto Triuno as a great option for puppies that require a monthly wormer on top of protection against fleas and ticks.
"This also gives flexibility later on for the dog to remain with the Bravecto brand but be swapped onto a longer-duration flea and tick product with a wormer administered according to a veterinarian’s risk-based assessment.”
Bravecto Triuno is available as a flavoured chewable tablet indicated for dogs and puppies from 8 weeks of age and at least 1.27 Kg body weight and can be administered monthly to dogs at risk of infestation by multiple types of internal and external parasites.
It contains three anti-parasitic ingredients including fluralaner, which provides activity against ticks and fleas, moxidectin, which provides systemic activity against non-intestinal worms, and pyrantel, which provides activity against intestinal worms.
https://www.noahcompendium.co.uk/?id=-488423
The one-hours session: "How do you recommend parasite treatments to your clients?" will be presented by Zoetis Veterinary Consultant Ruth Moxon MVB MRCVS.
Ruth will discuss how to structure advice and how to take the conversation away from the idea of ‘selling’ and towards a confident recommendation based on the pet’s needs.
The course will cover:
Ruth said: “We are aiming for attendees to leave the session feeling confident about discussing recommendations to clients on parasiticides.
"The talk will enable them to comfortably explain the features and benefits of the right parasiticide for that pet and owner in an objective way.”
The course is free to BVNA members.
Non-members are welcome to join the webinar at a cost of £15.00 per ticket.
To book, email: cpd@bvna.co.uk
Photo: BVNA
The panel will present the latest information on the prevalence of this zoonotic disease, review prevention strategies, and highlight the significance of cystic echinococcosis in humans.
The panelists are:
Dr Carolyn Kyte MRCVS (pictured), Elanco's UK Technical Consultant said: “We are concerned about potential changes in the distribution of Echinococcus granulosus in the UK and a subsequent change in zoonotic risk.
"We are hoping this cross-disciplinary discussion will provide Congress and Expo attendees with the latest insights the profession needs to allow individual, risk-based parasite control in dogs.
"The responsible use of parasiticides needs a true One-Health collaborative approach.”
"Reasons to be fearful? Rising proportions of positive faecal worm egg counts among UK horses (2007–2023)1" which was conducted in collaboration with Animal Health Vision International, the University of Liverpool and jDATA Pty (Ltd), analysed quarterly surveillance data summaries of FWEC test results that were submitted to the Equine Quarterly Disease Surveillance report (EQDSR) by 36 UK laboratories.
Of these, 18 laboratories provided additional details through a survey on the testing methods adopted.
The researchers say there was considerable variation between laboratories in both the FWEC test methods used and the FWEC positivity thresholds applied to designate a test result as positive for either surveillance reporting or for treatment purposes.
However, the analysis revealed an increase in the proportion of positive FWECs over time, even after accounting for the time of year that testing was conducted, the FWEC positivity threshold used for reporting a sample as positive and the laboratory undertaking the testing.
Researchers say these findings raise questions about targeted treatment strategies, where anthelmintics are administered if FWECs exceed a certain threshold.
If this threshold remains low, the increasing proportion of positive FWECs that were identified would lead to increased use of wormers, potentially accelerating the development of anthelmintic resistance.
This highlights the need to better understand the factors driving rising FWEC positivity rates and if they are a cause for concern.
For example, is this trend leading to increased numbers of horses exceeding the treatment threshold and therefore being recommended for treatment?
The study authors say that the continuation of coordinated efforts to enhance parasite control strategies across the UK equine industry is essential.
The recently available guidelines from the British Equine Veterinary Association (BEVA) and CANTER provide essential resources for vets, pharmacists and RAMAs/SQPs who prescribe equine anthelmintics to optimise parasite control2,3.
The new product is being sold through e-retailers including Pet Drugs Online, Animed and Pets at Home.
Frontpro is claimed to kill fleas within 8 hours and protect dogs from fleas and ticks for one month.
It is suitable for all breeds aged eight weeks or older (weighing two kilograms or more) and can be given with or without food.
A company spokesperson said: "Boehringer Ingelheim is committed to expanding access to high-quality parasite prevention for dogs, which is why we’re proud to introduce an effective new option.
"Frontpro chewable tablets provide effective protection from fleas and ticks, while complementing the regular care and advice pet owners receive from their veterinarians."
www.uk.frontline.com
The refreshed packaging keeps the same colour scheme, but the graphics indicating the product uses stand out better.
The company has also added an area on the side of the carton for owners to note the date each dose is given.
What can I say, it's a slow news day.
The materials include pet owner guides, reception posters and slides to display on waiting room TV.
They complement the Krka veterinary professional guide on responsible risk-based parasiticide use for cats and dogs that was developed in conjunction with Ian Wright BVMS MSc MRCVS and launched last year.
Renzo Di Florio, Krka’s Technical Veterinary Adviser said: “In first opinion veterinary practice, where the majority of consultations last 15 minutes or less, time is short and in-depth discussions are not always possible.
"The guides provide comprehensive information on common parasites, practical advice on prevention and treatment and information on risk assessment.
"And by aligning with ESCCAP guidelines, the guides help address the delicate balance between animal health, human health and environmental protection – a true One Health issue.”
https://www.krka.co.uk/veterinary-knowledge-hub/articles/risk-based-parasiticide-use-for-cats-and-dogs
This new injectable fluralaner formulation is approved for the immediate and persistent killing of fleas for one year (Ctenocephalides felis and Ctenocephalides canis), from 3 days to 12 months after treatment for the ticks Ixodes ricinus, and Dermacentor reticulatus, from 4 days to 12 months after treatment for Rhipicephalus sanguineus, and from 7 days to 12 months after treatment for Ixodes hexagonus.
MSD says it will also reduce the risk of Babesia canis via transmission by Dermacentor reticulatus from day 3 after treatment for up to 12 months, and also reduces the risk of infection with Dipylidium caninum via transmission by Ctenocephalides felis for up to 12 months.
Victoria Miles, UK Companion Animal Business Unit Director, MSD Animal Health said: “Imagine not having to worry about flea and tick protection for a whole year.
Bravecto 150 mg/ml powder and solvent for suspension for injection for dogs can be administered to dogs and puppies six months of age and older.
The product is already available in France and Germany and MSD told VetNurse.co.uk that stocks are expected in the UK in September, for which the company is now taking pre-orders.
Contact your MSD Account Manager for further information on pricing.
whatstherisk.co.uk has been created for all practice staff and contains advice from parasitologists Ian Wright and Eric Morgan.
Topics include advice on practical risk assessments, how risk-based prescribing can work with health plans as well as how to get owners involved to make risk assessment and personalised prescribing quicker and simpler.
Boehringer says that all the materials and advice have been developed in line with RCVS Practice Standards and the BVA's guidance on the responsible use of parasiticides.1,2
Sharron Woods, NexGard brands Franchise Manager said: “With knowledge about parasitic risk low among dog owners, alongside increasing scrutiny on the potential overuse of parasiticides, we’re delighted to be at the forefront of supporting vets, pet owners and the wider industry in driving best-practice risk assessment and responsible parasite control."
The decision was made after Council heard increasing reports that practices have not been keeping records of POM-V parasiticide prescriptions within patient records as has always been required by the VMD.
This created a bit of a problem when the new 'under care' guidance came into force at the start of this month, which requires that veterinary surgeons must perform a physical examination as part of their initial clinical assessment of an animal before prescribing POM-V anti-parasitics.
Failing a record of an existing prescription, that would have meant re-examining large numbers of animals at a time when resources in the profession are already stretched.
RCVS President, Sue Paterson, said: “While it has been both surprising and disappointing to learn of such widespread non-compliance with legislation that has been in place for many years, Council decided to postpone the implementation of this one aspect of our new under care guidance to allow practices additional time to bring their prescribing protocols into line."
The delayed implementation date of 12 January 2024 relates only to the prescription of POM-V anti-parasitics.
The rest of the new under care guidance remains in effect from 1 September 2023
Broadline was a fipronil-based parasiticide which also contained (S)-methoprene, eprinomectin and praziquantel.
NexGard Combo, on the other hand, contains esafoxolaner together with eprinomectin and praziquantel for worming.
Both products are licensed for use in cats with or at risk from mixed infestations by fleas, ticks, mites cestodes, nematodes.
There's an explainer video about NexGard Combo on the Boehringer Academy website: https://www.boehringer-academy.co.uk/
Concern has been expressed in the profession about environmental contamination from products used in companion animal treatment for ectoparasites, such as fleas and ticks.
In recent years there has been a widely documented fall in the abundance of many terrestrial invertebrate populations1.
While the decline has been mostly linked to agricultural chemicals, there is a concern that companion animal ectoparasiticides could also be a contributing factor, with a recent study2 confirming the presence of common compounds used in flea-treatment3 in UK waterways.
However, the association with companion animal ectoparasiticides is currently poorly understood, with a significant knowledge gap and little robust research available to assess the true importance and environmental consequences.
The funded project ‘Assessing the Environmental Risk from Ectoparasite Treatments in Companion Animals’ will be led by Professor Richard Wall, Professor of Zoology and Dr Emily Bell, Senior Lecturer at University of Bristol in collaboration with Dr Imogen Schofield, Veterinary Statistician and Epidemiologist at CVS, and Lizzie McLennan-Green, Small Animal Veterinary Director at CVS.
It will be conducted via a PhD studentship at the University of Bristol as part of the CVS Clinical Research Awards.
The research will include a longitudinal ‘citizen science’ study with pet owners to develop a greater understanding of owner use and attitudes towards ectoparasiticides.
It will also include laboratory assessments of ectoparasiticide residues collected from companion animals to provide evidence-based information on the potential environmental impact of the treatments when applied to companion animals.
It is hoped the study will help the wider veterinary profession develop the most appropriate approaches to prescribing and use of ectoparasiticides in the future, and inform educational strategies to support owners with ‘responsible use’. The study is also set to benefit companion animals, as the research will inform strategies to ensure the most appropriate control of parasitic burden to pets.
The project starts in January 2023 and will run for three-years as a full time PhD.
CVS is providing £95,000 to fund the research.